AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations ...
If you were to ask several life scientists to name a particular biochemical product that they simply could not do without, you'd probably get a myriad of answers that would mirror the research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results